Biobeat Raises $50M to Advance Cuffless Blood Pressure Monitor in U.S.

Biobeat Technologies has secured $50 million in a Series B round to commercialize its cuffless, 24-hour blood pressure monitoring patch in the U.S. The round was led by Ally Bridge Group, OrbiMed Advisors, and Elevage Medical, alongside an unnamed strategic investor.

The chest-worn patch offers a non-disruptive alternative to traditional ambulatory monitors, which rely on arm cuffs that inflate regularly, often disturbing sleep and causing incomplete readings. Biobeat’s device estimates blood pressure using pulse wave transit time, measuring the speed of a pressure wave from a heartbeat between two points. The company received 510(k) clearance for its latest version in January 2025.

Ambulatory monitoring can detect hypertension missed during one-time clinic visits, including elevated nighttime readings. Biobeat aims to improve patient compliance and position its device as a practical option for the roughly 100 million hypertensive patients in the U.S., despite current guidelines questioning the clinical benefit of cuffless technology.

06-01-2026